Use of Humanized Mouse Models in Drug Development - Brian Soper - 2024 EU Workshop Series
Read Flipbook
JAX at Festival of Biologics 2024
Jax is a top-tier research center and professional service provider combined into a unique institution. JAX was a pioneer in introducing humanized mice and remains a leader in developing these models. Derisk your drug development pipeline using models that recapitulate key aspects of human pathophysiology.
-
-
Loading, please wait
Error - something went wrong!
Schedule a Meeting with Adriano!
Thank you, we will be in touch soon.
-
The first comparative study of different lymphoma targeting ADCs in Humanized Mice - Tibor Schomber - 2024 EU Workshop Series
Read Flipbook
-
Application of Humanized Mice for Therapeutic Target Validation - Ali Roghenian - 2024 EU Workshop Series
Read Flipbook
-
HuPK Humanized FcRn Platform
Read Flipbook
-
Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies
During this webinar, we discuss preclinical data showcasing efficacy and safety testing of immunotherapies in immune humanized mouse models.
Watch Video
-
Evidence-Based Selection of the Starting Dose in First-in-Human Clinical Trials Using Humanized Mouse Models
Read Flipbook
-
Biologics Drug Development Gets an Upgrade with Humanized Animal Models
JAX Study Director Aaron Rose, Ph.D., explores how biological therapeutics are reshaping the drug development process and why humanized models are essential for advancing biologics programs.
Watch Video
-
Atlas Mice Developed by AbTherx
Read Flipbook
-
CAR T-induced Immunotoxicity: Tackling the Cytokine Release Syndrome Challenge
In this special joint webinar, we discuss CAR T-induced Immunotoxicity, highlighting cutting-edge platforms for assessing the safety and efficacy of CAR therapies and preventing the development of CRS
Watch Video
-
JAX Humanized Mice PubCast: CD19-CD28 Bispecific + FcRn mouse model to predict human PK
In this PubCast, we delve into Roche’s integration of humanized mice in their preclinical drug development pipeline to assess the safety and efficacy of their CD19-CD28 bispecific.
Watch Video
